Petra Andršová, Jitka Prachařová, Vojtěch Novohradský, Slavomíra Šterbinská, Pavel Štarha, Jana Kašpárková, Viktor Brabec
{"title":"含蒽和联苯取代基的半夹层铑(III)配合物对哺乳动物癌细胞和多细胞肿瘤球体的光毒性","authors":"Petra Andršová, Jitka Prachařová, Vojtěch Novohradský, Slavomíra Šterbinská, Pavel Štarha, Jana Kašpárková, Viktor Brabec","doi":"10.1021/acs.jmedchem.5c01406","DOIUrl":null,"url":null,"abstract":"We report the synthesis and characterization of three half-sandwich rhodium(III) complexes incorporating anthracene and biphenyl moieties to investigate their photobiological activity. Complexes <b>1</b> and <b>2</b>, bearing anthracene-based Schiff base ligand, displayed pronounced phototoxicity upon blue-light irradiation, with complex <b>2</b> achieving a phototoxicity index of 144 in A375 melanoma cells. In contrast, complex <b>3</b>, lacking the anthracene unit, was photoinactive. Photoactivation of complexes <b>1</b> and <b>2</b> induced −N═CH– Schiff bond cleavage, releasing anthracene-9-carbaldehyde, as confirmed by UV–vis and mass spectrometry. Blue light also enabled catalytic oxidation of NADH to NAD<sup>+</sup>. Mechanistic studies revealed oncosis-like cell death mediated by reactive oxygen species. Both complexes retained activity in 3D tumor spheroids, demonstrating efficient tissue penetration. These results identify anthracene-functionalized rhodium(III) complexes as promising candidates for photodynamic therapy and provide, to our knowledge, the first detailed mechanistic insight into photopotentiation in half-sandwich rhodium systems.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phototoxicity of Half-Sandwich Rhodium(III) Complexes with Anthracene and Biphenyl Substituents toward Mammalian Cancer Cells and Multicellular Tumor Spheroids\",\"authors\":\"Petra Andršová, Jitka Prachařová, Vojtěch Novohradský, Slavomíra Šterbinská, Pavel Štarha, Jana Kašpárková, Viktor Brabec\",\"doi\":\"10.1021/acs.jmedchem.5c01406\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We report the synthesis and characterization of three half-sandwich rhodium(III) complexes incorporating anthracene and biphenyl moieties to investigate their photobiological activity. Complexes <b>1</b> and <b>2</b>, bearing anthracene-based Schiff base ligand, displayed pronounced phototoxicity upon blue-light irradiation, with complex <b>2</b> achieving a phototoxicity index of 144 in A375 melanoma cells. In contrast, complex <b>3</b>, lacking the anthracene unit, was photoinactive. Photoactivation of complexes <b>1</b> and <b>2</b> induced −N═CH– Schiff bond cleavage, releasing anthracene-9-carbaldehyde, as confirmed by UV–vis and mass spectrometry. Blue light also enabled catalytic oxidation of NADH to NAD<sup>+</sup>. Mechanistic studies revealed oncosis-like cell death mediated by reactive oxygen species. Both complexes retained activity in 3D tumor spheroids, demonstrating efficient tissue penetration. These results identify anthracene-functionalized rhodium(III) complexes as promising candidates for photodynamic therapy and provide, to our knowledge, the first detailed mechanistic insight into photopotentiation in half-sandwich rhodium systems.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.5c01406\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c01406","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Phototoxicity of Half-Sandwich Rhodium(III) Complexes with Anthracene and Biphenyl Substituents toward Mammalian Cancer Cells and Multicellular Tumor Spheroids
We report the synthesis and characterization of three half-sandwich rhodium(III) complexes incorporating anthracene and biphenyl moieties to investigate their photobiological activity. Complexes 1 and 2, bearing anthracene-based Schiff base ligand, displayed pronounced phototoxicity upon blue-light irradiation, with complex 2 achieving a phototoxicity index of 144 in A375 melanoma cells. In contrast, complex 3, lacking the anthracene unit, was photoinactive. Photoactivation of complexes 1 and 2 induced −N═CH– Schiff bond cleavage, releasing anthracene-9-carbaldehyde, as confirmed by UV–vis and mass spectrometry. Blue light also enabled catalytic oxidation of NADH to NAD+. Mechanistic studies revealed oncosis-like cell death mediated by reactive oxygen species. Both complexes retained activity in 3D tumor spheroids, demonstrating efficient tissue penetration. These results identify anthracene-functionalized rhodium(III) complexes as promising candidates for photodynamic therapy and provide, to our knowledge, the first detailed mechanistic insight into photopotentiation in half-sandwich rhodium systems.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.